ALK Fusion and Its Association with Other Driver Gene Mutations in Finnish Non-Small Cell Lung Cancer Patients
作者： Katja Tuononen , Mia Kero , Satu Mäki-Nevala , Virinder Kaur Sarhadi , Milja Tikkanen
DOI: 10.1002/GCC.22198
关键词: Immunohistochemistry 、 Anaplastic lymphoma kinase 、 Fluorescence in situ hybridization 、 Bioinformatics 、 Carcinoma 、 Lung cancer 、 Cancer research 、 Biology 、 Gene mutation 、 Anaplastic Lymphoma 、 Fusion gene
摘要: Screening of anaplastic lymphoma tyrosine kinase (ALK) gene fusions in non-small cell lung cancer (NSCLC) patients enables the identification likely to benefit from ALK-targeted therapy. Our aim was assess prevalence ALK fusion Finnish NSCLC patients, which has not been reported earlier, and study presence relation clinicopathological characteristics other driver mutations. A total 469 formalin-fixed paraffin-embedded tumor tissue specimens were screened for by immunohistochemistry (IHC). For confirmation IHC results, fluorescence situ hybridization (FISH) conducted 171 specimens. Next-generation sequencing performed all ALK-positive characterize association with mutations targeted regions 22 genes. Of tumors screened, 11 (2.3%) harbored an fusion, including nine adenocarcinomas two large carcinomas. The results 160 random ALK-negative confirmed FISH. significantly associated never/ex-light smoking history (P<0.001) younger age (P=0.004). Seven showed additional mutations; three MET, one MET CTNNB1, TP53, PIK3CA. show that is infrequent alteration patients. Although majority cases adenocarcinomas, also seen Further studies are needed elucidate clinical significance coexistence PIK3CA
sci-hub.se 参考文章(24)
Masakuni Serizawa, Yasuhiro Koh, Hirotsugu Kenmotsu, Mitsuhiro Isaka, Haruyasu Murakami, Hiroaki Akamatsu, Keita Mori, Masato Abe, Isamu Hayashi, Tetsuhiko Taira, Tomohiro Maniwa, Toshiaki Takahashi, Masahiro Endo, Takashi Nakajima, Yasuhisa Ohde, Nobuyuki Yamamoto, Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: A prospective, single-institute study Cancer. ,vol. 120, pp. 1471- 1481 ,(2014) , 10.1002/CNCR.28604
Sven Perner, Patrick L Wagner, Francesca Demichelis, Rohit Mehra, Christopher J LaFargue, Benjamin J Moss, Stefanie Arbogast, Alex Soltermann, Walter Weder, Thomas J Giordano, David G Beer, David S Rickman, Arul M Chinnaiyan, Holger Moch, Mark A Rubin, EML4-ALK Fusion Lung Cancer: A Rare Acquired Event Neoplasia. ,vol. 10, pp. 298- 302 ,(2008) , 10.1593/NEO.07878
Isamu Okamoto, Kazuko Sakai, Satoshi Morita, Hiroshige Yoshioka, Hiroyasu Kaneda, Koji Takeda, Tomonori Hirashima, Yoshihito Kogure, Tatsuo Kimura, Toshiaki Takahashi, Shinji Atagi, Takashi Seto, Toshiyuki Sawa, Masashi Yamamoto, Miyako Satouchi, Motoyasu Okuno, Seisuke Nagase, Koichi Takayama, Keisuke Tomii, Tadashi Maeda, Satoshi Oizumi, Shinji Fujii, Yusaku Akashi, Kazumi Nishino, Noriyuki Ebi, Kazuhiko Nakagawa, Yoichi Nakanishi, Kazuto Nishio, Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study Oncotarget. ,vol. 5, pp. 2293- 2304 ,(2014) , 10.18632/ONCOTARGET.1906
Prateek Kumar, Steven Henikoff, Pauline C Ng, Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature Protocols. ,vol. 4, pp. 1073- 1081 ,(2009) , 10.1038/NPROT.2009.86
Katja Tuononen, Virinder Kaur Sarhadi, Aino Wirtanen, Mikko Rönty, Kaisa Salmenkivi, Aija Knuuttila, Satu Remes, Aino I. Telaranta-Keerie, Stuart Bloor, Pekka Ellonen, Sakari Knuutila, Targeted Resequencing Reveals ALK Fusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods BioMed Research International. ,vol. 2013, pp. 757490- 757490 ,(2013) , 10.1155/2013/757490
Jennifer M. Boland, Jin Sung Jang, Jun Li, Adam M. Lee, Jason A. Wampfler, Michele R. Erickson-Johnson, Ibere Soares, Ping Yang, Jin Jen, Andre M. Oliveira, Eunhee S. Yi, MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Journal of Thoracic Oncology. ,vol. 8, pp. 574- 581 ,(2013) , 10.1097/JTO.0B013E318287C395
Hang Li, Yunjian Pan, Yuan Li, Chenguang Li, Rui Wang, Haichuan Hu, Yang Zhang, Ting Ye, Lei Wang, Lei Shen, Yihua Sun, Haiquan Chen, Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose. Lung Cancer. ,vol. 79, pp. 8- 13 ,(2013) , 10.1016/J.LUNGCAN.2012.09.018
Junko Tanizaki, Isamu Okamoto, Kunio Okamoto, Ken Takezawa, Kiyoko Kuwata, Haruka Yamaguchi, Kazuhiko Nakagawa, MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. Journal of Thoracic Oncology. ,vol. 6, pp. 1624- 1631 ,(2011) , 10.1097/JTO.0B013E31822591E9
Kentaro Inamura, Kengo Takeuchi, Yuki Togashi, Satoko Hatano, Hironori Ninomiya, Noriko Motoi, Ming-yon Mun, Yukinori Sakao, Sakae Okumura, Ken Nakagawa, Manabu Soda, Young Lim Choi, Hiroyuki Mano, Yuichi Ishikawa, EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Modern Pathology. ,vol. 22, pp. 508- 515 ,(2009) , 10.1038/MODPATHOL.2009.2
Lei Wang, Haichuan Hu, Yunjian Pan, Rui Wang, Yuan Li, Lei Shen, Yongfu Yu, Hang Li, Deng Cai, Yihua Sun, Haiquan Chen, PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup PLoS ONE. ,vol. 9, pp. e88291- ,(2014) , 10.1371/JOURNAL.PONE.0088291